NCT07116824尚未招募2 期
A Phase II Trial to Evaluate the Safety and Efficacy of HB1801 Combination Therapy as First-line Treatment in HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.0 个研究点目标入组 80 人开始时间: 2025年9月15日最近更新:
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 80
- 主要终点
- Objective Response Rate (ORR) as assessed by RECIST 1.1
研究概览
简要总结
This study is designed to evaluate the safety and efficacy of HB1801 combination therapy as first-line treatment in HER2-positive unresectable locally advanced or metastatic breast cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Voluntarily participate in this study and sign the Informed Consent Form (ICF);
- •Age ≥ 18 years;
- •Histologically and/or cytologically confirmed unresectable locally recurrent or metastatic breast cancer;
- •HER2-positive (IHC 3+, or IHC 2+ with ISH-positive);
- •No prior systemic chemotherapy and/or HER2-targeted therapy for unresectable locally recurrent or metastatic breast cancer (participants who have received ≤1 line of endocrine therapy are eligible); Participants who relapsed >12 months after completing (neo)adjuvant chemotherapy or HER2-targeted therapy may be considered for enrollment;
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;
- •At least one measurable lesion per RECIST 1.
- •The measurable lesion should not have received local treatment such as radiotherapy (lesions in previously irradiated areas may be selected as target lesions if progression is confirmed). Target lesions cannot be bone-only metastases;
- •Adequate organ and bone marrow function (without transfusion or hematopoietic growth factor support within 14 days prior to testing):
- •Absolute neutrophil count (ANC) ≥ 1.5 × 10^9/L;
- •Platelet count ≥ 100 × 10^9/L;
- •Hemoglobin ≥ 90 g/L;
- •Liver function: Total bilirubin (TBIL) ≤ 1.0 × upper limit of normal (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN (ALT/AST≤ 5 × ULN for participants with liver metastases; AST/ALT ≤ 1.5 × ULN for participants with alkaline phosphatase (ALP) > 2.5 × ULN);
- •Renal function: Creatinine clearance ≥60 mL/min (calculated by Cockcroft-Gault formula);
- •Coagulation: International normalized ratio (INR) ≤ 1.5 and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN (for participants receiving anticoagulation therapy, the investigator should confirm that INR and APTT are within safe and effective therapeutic ranges);
- •Left ventricular ejection fraction (LVEF) > 50%;
- •Expected survival ≥ 3 months;
- •For women of childbearing potential: Negative serum pregnancy test within 7 days before randomization and agreement to use reliable contraception during the study and for 3 months after last dose of docetaxel/HB1801 or 7 months after last dose of trastuzumab/pertuzumab (whichever is longer). For male participants with partners of childbearing potential: Agreement to use reliable contraception during the study and for 3 months after last dose of docetaxel/HB1801 or 7 months after last dose of trastuzumab/pertuzumab (whichever is longer).
排除标准
- •Contraindications to trastuzumab, pertuzumab, or docetaxel, or deemed by the investigator as unsuitable for treatment with HB1801, docetaxel, pertuzumab, or trastuzumab;
- •Participants with ≥ Grade 3 peripheral neuropathy at randomization;
- •Toxicities from prior anticancer therapy have not resolved to ≤ Grade 1 per CTCAE v5.0 (except for alopecia, peripheral neuropathy, or laboratory abnormalities deemed non-risky by the investigator, which must be ≤ Grade 2);
- •History of LVEF decline to < 50%, symptomatic congestive heart failure (CHF), or toxicity leading to permanent discontinuation during prior HER2-targeted therapy;
- •Known hypersensitivity or contraindications to corticosteroids (including but not limited to active peptic ulcer, severe hypertension, severe hypokalemia, glaucoma, etc.);
- •Prior anthracycline therapy exceeding cumulative doses of: Doxorubicin or liposomal doxorubicin > 360 mg/m², Epirubicin > 720 mg/m², Mitoxantrone > 120 mg/m², Other anthracyclines > doxorubicin-equivalent 360 mg/m²(If multiple anthracyclines were used, the total dose must not exceed 360 mg/m² doxorubicin-equivalent);
- •Use of strong CYP3A4 inhibitors within 14 days before randomization;
- •History of hypersensitivity to any study drug component or excipients;
- •Untreated or unstable brain/spinal metastases, leptomeningeal disease, or cord compression (participants with treated, asymptomatic CNS lesions stable for ≥4 weeks on imaging, without edema, and off corticosteroids may be eligible);
- •Active malignancies within 3 years prior to randomization, except: studied breast cancer, locally cured tumors (e.g., resected basal/squamous skin cancer, superficial bladder cancer, cervical/breast carcinoma in situ, early-stage thyroid cancer);
- •Uncontrolled or significant cardiovascular disease, including:
- •NYHA Class II+ CHF, unstable angina, myocardial infarction, or hemodynamically unstable arrhythmia within 6 months;
- •Primary cardiomyopathy (e.g., dilated, hypertrophic, arrhythmogenic right ventricular, restrictive);
- •Clinically significant QTc prolongation (Fridericia-corrected QTcF > 450 ms at screening);
- •Arterial/venous thromboembolism within 6 months (e.g., stroke, TIA, DVT, PE);
- •Uncontrolled hypertension (SBP > 160 mmHg and/or DBP > 100 mmHg);
- •Active/chronic infection requiring systemic antimicrobial/antiviral therapy within 14 days (including tuberculosis);
- •Active hepatitis: HBV (HBsAg+ with HBV-DNA ≥ 2×10³ IU/mL), HCV (anti-HCV+ with detectable HCV-RNA) *Note: HBsAg+ carriers with HBV-DNA < 2×10³ IU/mL may enroll if willing to receive entecavir/antiviral therapy;*
- •Known HIV infection;
- •Concurrent participation in other interventional clinical trials (except observational studies or follow-up phases) or <4 weeks since last dose in prior interventional trials;
- •Anticancer therapy within 28 days (radiotherapy, targeted/immunotherapy, investigational drugs) or 14 days (traditional Chinese medicine with antitumor indications);
- •Uncontrolled effusions requiring frequent drainage/medical intervention within 7 days (e.g., pleural, ascites, pericardial) or needing re-intervention within 2 weeks (excluding cytology);
- •Major surgery within 28 days (excluding biopsies);
- •Pregnant or lactating women;
- •Other conditions compromising study participation/benefit (e.g., psychiatric disorders, substance abuse, or clinically significant comorbidities).
研究组 & 干预措施
Cohort 1：Combination of HB1801, Trastuzumab and Pertuzumab
Experimental
HB1801: per protocol; Trastuzumab: 8mg/kg loading dose and then 6mg/kg, Q3W; Pertuzumab: 840mg loading dose and then 420mg, Q3W
干预措施: HB1801 (Drug)
Cohort 1：Combination of HB1801, Trastuzumab and Pertuzumab
Experimental
HB1801: per protocol; Trastuzumab: 8mg/kg loading dose and then 6mg/kg, Q3W; Pertuzumab: 840mg loading dose and then 420mg, Q3W
干预措施: Trastuzumab (Drug)
Cohort 1：Combination of HB1801, Trastuzumab and Pertuzumab
Experimental
HB1801: per protocol; Trastuzumab: 8mg/kg loading dose and then 6mg/kg, Q3W; Pertuzumab: 840mg loading dose and then 420mg, Q3W
干预措施: Pertuzumab (Drug)
Cohort 2：Combination of Docetaxel, Trastuzumab and Pertuzumab
Active Comparator
Docetaxel：75mg/m^2 ，Q3W Trastuzumab: 8mg/kg loading dose and then 6mg/kg, Q3W; Pertuzumab: 840mg loading dose and then 420mg, Q3W
干预措施: Trastuzumab (Drug)
Cohort 2：Combination of Docetaxel, Trastuzumab and Pertuzumab
Active Comparator
Docetaxel：75mg/m^2 ，Q3W Trastuzumab: 8mg/kg loading dose and then 6mg/kg, Q3W; Pertuzumab: 840mg loading dose and then 420mg, Q3W
干预措施: Pertuzumab (Drug)
Cohort 2：Combination of Docetaxel, Trastuzumab and Pertuzumab
Active Comparator
Docetaxel：75mg/m^2 ，Q3W Trastuzumab: 8mg/kg loading dose and then 6mg/kg, Q3W; Pertuzumab: 840mg loading dose and then 420mg, Q3W
干预措施: Docetaxel (Drug)
结局指标
主要结局
Objective Response Rate (ORR) as assessed by RECIST 1.1
时间窗: Up to approximately 2 years
次要结局
- Disease Control Rate (DCR) as assessed by RECIST 1.1(Up to approximately 2 years)
- Duration of Response (DoR) as assessed by RECIST 1.1(Up to approximately 2 years)
- Progression-free survival (PFS) as assessed by RECIST 1.1(Up to approximately 2 years)
- Overall Survival (OS)(Up to approximately 2 years)
- Incidence and severity of treatment-emergent adverse events (TEAE)(Up to approximately 2 years)
研究者
相似试验
撤回
2 期
Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast CancerEstrogen Receptor NegativeHER2/Neu NegativeProgesterone Receptor NegativeRecurrent Breast CarcinomaTriple Negative Breast CancerMetastatic Breast CancerNCT03644589University of Washington
已完成
1 期
Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosisPost Essential Thrombocythemia MyelofibrosisPost Polycythemia-Vera MyelofibrosisIdiopathic MyelofibrosisNCT01433445Novartis Pharmaceuticals61
招募中
2 期
A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung CancerNon-small Cell Lung CancerNCT06498986Sichuan Baili Pharmaceutical Co., Ltd.40
招募中
1 期
A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.HER2-expressing Advanced Solid TumorsNCT06015048Jiangsu HengRui Medicine Co., Ltd.364
招募中
2 期
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast CancerTriple-negative Breast CancerNCT06471205Sichuan Baili Pharmaceutical Co., Ltd.52